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OBJECTIVES: The aim of this study is to estimate the cost-
effectiveness ratio of Duloxetine compared to Venlafaxine in the
management of major depression in Portugal. A model developed
by MEDTAP International Inc. was adapted in order to reﬂect
clinical practice in Portugal. METHODS: The model allows for
the estimation of costs, QALY, the proportion of patients achiev-
ing remission, and the average time spent in remission by each
patient during one year. The societal perspective was adopted. In
each cycle a patient may drop-out, achieve remission, respond to
treatment not achieving remission, or have no response. Clinical
evaluation is based on patients’ scores in the Hamilton scale.
Patients that do not achieve remission may have their dose
adjusted, switch to or add another anti-depressant. Clinical data
was taken from a randomized controlled trial between Duloxet-
ine and Venlafaxine. Results show that Duloxetine allows more
patients to achieve remission, despite the fact that less patients
achieve response. Duloxetine is also associated with a higher
proportion of patients with adverse events. Recurrence and
relapse rates were taken from the literature. Quality of life and
resource consumption data were collected through a Delphi
panel of psychiatrists with large clinical experience. Ofﬁcial
sources were used to get unit costs. RESULTS: Patient that start
treatment with Duloxetine spend 34.5 weeks in remission, with
83.9% achieving remission at the end of the period. As a conse-
quence, Duloxetine enables 0.708 QALYs per patient. Those
who start treatment with Venlafaxine stay in remission during 34
weeks, with 83.5% achieving remission at the end of the period.
Therefore, Venlafaxine treated patients beneﬁt from 0.698
QALYs. Duloxetine also allows for savings in resources used. It
implies a total expenditure of €1126 per patient while Venlafax-
ine related expenditure equates to €1231. CONCLUSIONS:
Duloxetine is more effective and less costly, being a dominant
alternative.
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OBJECTIVES: While the substantial health care cost of depres-
sion in the workplace is well documented, less is known about
the impact of depression severity on workplace burden. The
objective is to document workplace burden of major depressive
disorder (MDD) by severity. METHODS: Using U.S. data from
the National Comorbidity Survey-Replication, workforce
respondents (n = 4465) were classiﬁed into clinical severity cat-
egories (not clinically depressed, mild, moderate, severe) using
standard scales (CIDI/QIDS-SR). Outcomes included employ-
ment status (employed, disabled, unemployed), workplace per-
formance (measured as hours worked, self-rated performance,
days of missed work), and workplace burden (estimated by mul-
tiplying work hours lost by self-reported hourly income, from
HPQ). Outcomes were compared across depression severity
groups using multivariate models that adjusted for demographic
characteristics. Total monthly US burden of reduced work and
performance was estimated through extrapolation using govern-
ment workforce statistics. RESULTS: Among the 539 depressed
respondents, 13.8% were mild, 38.5% moderate and 47.7%
severely depressed. Respondents shared similar demographic
characteristics across severity levels. Depressed respondents were
2.6 times more likely to be unemployed/disabled than non-
depressed respondents (p < 0.001). The prevalence rates of
unemployment/disability increased with depression severity:
15.7%, 23.3% and 31.3% for mild, moderate and severely
depressed respondents respectively (p < 0.01). Moderately and
severely depressed employed respondents were 4–5% less pro-
ductive than mildly depressed/non-depressed respondents (p <
0.01). Severity is negatively associated with work performance.
Compared to non-depressed respondents, mildly depressed
respondents have reduced monthly workplace performance by
3.0 hours (not statistically signiﬁcant), vs.12.0 hours (14.8
hours) for moderately (severely) depressed respondents (p <
0.001) The monthly cost of lost performance was $188 ($199)
per moderately (severely) depressed worker; the total monthly
U.S. burden of reduced work and performance is $2.1 billion/
month. CONCLUSIONS: Among MDD respondents in the
workforce, there was a positive association between depression
severity and rates of unemployment and disability. Depression is
also negatively associated with work performance.
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OBJECTIVES: Cost analysis of the changes in hospitalisation for
patients with schizophrenia in Spain over a 25-year period
(1980–2004). METHODS: Cost analysis of the hospitalisation
for patients with schizophrenia over a 25-year period based on
the data exploited from the Spanish National hospital utilization
databases: Minimum Basic Data Set and Survey of Hospital
Morbidity. Taking into account the changes in the number of
admission episodes, average length of stay (LOS) of such epi-
sodes, and costs generated per stay, an estimation of the varying
hospitalisation costs in this period was carried out. RESULTS:
Our data shows that the trend in hospitalisation rates for schizo-
phrenics has increased over the entire period (3.70 in 1980 to
5.89 in 2004). LOS has substantially decreased during the study
period from 148 days in 1980 to 36 days in 2004. The estimated
cost per day in a psychiatric hospital for a schizophrenic patient
in Spain in the year 2000 was €215.60. Some factors affecting the
cost of inpatient treatment has been the evolution, consumption
pattern and pharmaceutical cost of the antipsychotic drugs used
in the treatment of these patients. From 1990–2001, antipsy-
chotic consumption has almost doubled from 3.31 DID (Daily
deﬁned dose, DDD, per 1000 inhabitants and per day of treat-
ment) to 6.04 DID. The cost of these drugs has increased 13
times, mainly due to the increase in the cost of atypical antipsy-
chotics which has risen from representing less than 1% of the
total cost in 1993 to representing 92% in 2001. The DDD cost
has risen, in constant euros, from, €6.48 in 1990 to €20.31 in
2001. In addition, as a growing number of patients are being
taken care of in the community, as supported by the deinstitu-
tionalisation process, admissions into other types of institutions
should be considered. There are studies showing an increase in
the number of places in residential care and supervised and
supported housing, having doubled in Spain from 5.1 per
100.000 population in 1990 to 10.6 in 2006. Of course, the costs
per day vary greatly depending on the institution where the
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schizophrenic patient is placed, ranging from €67.4 per day in a
day centre, to €164 per day in a long term residency or €315.7
per day in a mental health unit of a general hospital, where most
stays are currently taking place in Spain. CONCLUSIONS: Fol-
lowing the deinstitutionalisation process of psychiatric patients
that has occurred in most Western countries, in Spain, we observe
an increase in admissions rates linked to a decrease in LOS for
schizophrenic patients. The changing patterns of use of hospital
resources parallel to the changes in community care, mean that
the costs have varied complementarily throughout this reform
process. These trends could have important implications for
policy makers and health care providers.
MENTAL HEALTH—Patient-Reported Outcomes Studies
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Poor compliance of schizophrenic patients is well known and
linked to negative treatment outcomes. To address persistent
issues of compliance we need to adopt a more patient centric
approach towards evaluation of medicine with an aim to better
appreciate the requirements of patients. OBJECTIVES: To iden-
tify patient requirements towards drug characteristics, with
further emphasis on route of administration, and to examine
if attitudes are modiﬁed with experience with a depot.
METHODS: Based on 13 relevant drug characteristics, extracted
through patient focus groups [n = 20] and literature a survey
instrument was developed. Respondents were asked to rank and
then rate the factors using 5-point Likert scales. Respondents
included depot naïve [n = 33], depot experienced [n = 34], and
patients currently on depot [n = 38]). Data was analyzed using
descriptive statistics. RESULTS: In aggregate, patients ranked
avoidance of dyskinesia (79.25), positive inﬂuence on sleep
(75.25), onset of action (72.75), and no/little weight gain (72.25)
as important drug characteristics. The least rated factors were
no/little interaction with alcohol (52.75) and drug costs (53.5).
With regard to differences between patients experiences with a
depot, current depot users gave frequency of application a higher
ranking (Rank 4 vs. Ranks 8,8). The preference for a depot
formulation was highly dependent on previous experience
(depot: 84%, depot experience: 29%, depot-naïve: 3%, p <
0.05), with an overall preferred frequency of injection every
four weeks. CONCLUSIONS: Patients with Schizophrenia are
capable and willing to share their attitudes about key processes
related to the medical management of schizophrenia. Incorporat-
ing patient preferences into decision making offers an opportu-
nity to better understand issues of adherence and management of
therapy. Experience with a depot medication seems to lead
to higher acceptance and appreciation of such formulations.
More research is need to understand if these differences are
related a optimal selection of medication or a learning by doing
phenomena.
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OBJECTIVES: Considering the patients point of view in treat-
ment decision making is crucial for a successful therapy. In con-
trast to somatic diseases in schizophrenia there are only few
examples where the patients attitude and point of view was
systematically recorded. Objective of the study was to collect the
attitude of schizophrenic patients towards generic substitution of
atypical antipsychotics. METHODS: In the quantitative survey
schizophrenic patients, capable to give one’s consent, aged 18–60
years were interviewed on the basis of a structured questionnaire.
All participants received a second generation antipsychotic for at
least one year. Getting in contact with the patients was facilitated
via practice-based psychiatrists who secured the recruitment of
the appropriate patients in line with the screening criteria.
RESULTS: The survey was conducted in November/December
2007. 104 patients (Æ 41.2  11.1 yrs.; Æ treatment duration
3.5  3.2 yrs.). According to the patients’ information drug
treatment was changed 1.7 times on average during the last 5
years (range 1–14). In case of a generic substitution initiated by
the attending physician 69% of the patients expressed a willing-
ness to take the medication further on. The acceptance of a
treatment switch was reduced if the switch was not justiﬁed by a
lack of efﬁcacy/tolerability (28%). Especially the regular switch
of drugs with the same agent in the pharmacy would be met with
a refusal as voiced by 76% of the patients. CONCLUSIONS: The
study shows that the conduction of a quantitative survey with
schizophrenic patients is feasible and differentiated statements
regarding patients’ attitudes towards pharmacotherapy can be
generated. The results emphasize the importance of an extensive
education of the patients prior to a generic substitution in order
to support therapy adherence, which is fragile per se. Physicians
are expected to fulﬁll this educational task.
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Patient preferences are an important indicator of patients’ under-
lying values and could enlighten literatures on both compliance
and satisfaction with treatment. Patient preference methods,
such as conjoint analysis, are increasingly used in clinical areas,
but applications in mental health remain limited. OBJECTIVES:
To determine the capability of patients with schizophrenia to
complete a conjoint analysis questionnaire, document patients’
reactions to conjoint tasks and assess the validity and reliability
of their responses. METHODS: Attributes and levels relating to
the medical management of schizophrenia were identiﬁed
through patient focus groups and literature reviews to create
simple conjoint analysis task of six attributes with two levels
each. Respondents (n = 25) were patients diagnosed with at least
one episode of schizophrenia, presently stable and undergoing
therapy with a neuroleptic medication and were recruited
through clinics from four cities in Germany. The majority of
respondents were presented with eight paired-comparisons; but
a limited number of respondents were presented with sets of four
scenarios to test satiation. Questionnaires were administered in
person with limited explanation, were audio recorded and later
analyzed. RESULTS: Respondents easily completed the conjoint
tasks and results were consistent with underlying hypotheses.
Speciﬁcally we identiﬁed four statistically signiﬁcant factors: i)
ability to think clearly (p > 0.001); ii) tiredness (p > 0.001); iii)
having a supportive physician (p > 0.001); and iv) the ability to
participate in social activities (p > 0.005). The reliability of
responses based test-retest was high, 82.35% agreement between
responses, Kappa 0.648 (p > 0.0001). Patients could also com-
plete more complicated tasks based on choice among four
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